Development of proneurogenic, neuroprotective small molecules

Karen S. MacMillan, Jacinth Naidoo, Jue Liang, Lisa Melito, Noelle S. Williams, Lorraine Morlock, Paula J. Huntington, Sandi Jo Estill, Jamie Longgood, Ginger L. Becker, Steven L. McKnight, Andrew A. Pieper, Jef K. De Brabander, Joseph M. Ready

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Degeneration of the hippocampus is associated with Alzheimer's disease and occurs very early in the progression of the disease. Current options for treating the cognitive symptoms associated with Alzheimer's are inadequate, giving urgency to the search for novel therapeutic strategies. Pharmacologic agents that safely enhance hippocampal neurogenesis may provide new therapeutic approaches. We discovered the first synthetic molecule, named P7C3, which protects newborn neurons from apopotic cell death, and thus promotes neurogenesis in mice and rats in the subgranular zone of the hippocampal dentate gyrus, the site of normal neurogenesis in adult mammals. We describe the results of a medicinal chemistry campaign to optimize the potency, toxicity profile, and stability of P7C3. Systematic variation of nearly every position of the lead compound revealed elements conducive toward increases in activity and regions subject to modification. We have discovered compounds that are orally available, nontoxic, stable in mice, rats, and cell culture, and capable of penetrating the blood-brain barrier. The most potent compounds are active at nanomolar concentrations. Finally, we have identified derivatives that may facilitate mode-of-action studies through affinity chromatography or photo-cross-linking.

Original languageEnglish (US)
Pages (from-to)1428-1437
Number of pages10
JournalJournal of the American Chemical Society
Volume133
Issue number5
DOIs
StatePublished - Feb 9 2011

Fingerprint

Neurogenesis
Rats
Lead compounds
Affinity chromatography
Molecules
Mammals
Cell death
Cell culture
Neurons
Toxicity
Parahippocampal Gyrus
Neurobehavioral Manifestations
Pharmaceutical Chemistry
Dentate Gyrus
Derivatives
Blood-Brain Barrier
Affinity Chromatography
Disease Progression
Hippocampus
Alzheimer Disease

ASJC Scopus subject areas

  • Chemistry(all)
  • Catalysis
  • Biochemistry
  • Colloid and Surface Chemistry

Cite this

Development of proneurogenic, neuroprotective small molecules. / MacMillan, Karen S.; Naidoo, Jacinth; Liang, Jue; Melito, Lisa; Williams, Noelle S.; Morlock, Lorraine; Huntington, Paula J.; Estill, Sandi Jo; Longgood, Jamie; Becker, Ginger L.; McKnight, Steven L.; Pieper, Andrew A.; De Brabander, Jef K.; Ready, Joseph M.

In: Journal of the American Chemical Society, Vol. 133, No. 5, 09.02.2011, p. 1428-1437.

Research output: Contribution to journalArticle

MacMillan, KS, Naidoo, J, Liang, J, Melito, L, Williams, NS, Morlock, L, Huntington, PJ, Estill, SJ, Longgood, J, Becker, GL, McKnight, SL, Pieper, AA, De Brabander, JK & Ready, JM 2011, 'Development of proneurogenic, neuroprotective small molecules', Journal of the American Chemical Society, vol. 133, no. 5, pp. 1428-1437. https://doi.org/10.1021/ja108211m
MacMillan, Karen S. ; Naidoo, Jacinth ; Liang, Jue ; Melito, Lisa ; Williams, Noelle S. ; Morlock, Lorraine ; Huntington, Paula J. ; Estill, Sandi Jo ; Longgood, Jamie ; Becker, Ginger L. ; McKnight, Steven L. ; Pieper, Andrew A. ; De Brabander, Jef K. ; Ready, Joseph M. / Development of proneurogenic, neuroprotective small molecules. In: Journal of the American Chemical Society. 2011 ; Vol. 133, No. 5. pp. 1428-1437.
@article{9da06f61073041b49bb31663c1e0cae4,
title = "Development of proneurogenic, neuroprotective small molecules",
abstract = "Degeneration of the hippocampus is associated with Alzheimer's disease and occurs very early in the progression of the disease. Current options for treating the cognitive symptoms associated with Alzheimer's are inadequate, giving urgency to the search for novel therapeutic strategies. Pharmacologic agents that safely enhance hippocampal neurogenesis may provide new therapeutic approaches. We discovered the first synthetic molecule, named P7C3, which protects newborn neurons from apopotic cell death, and thus promotes neurogenesis in mice and rats in the subgranular zone of the hippocampal dentate gyrus, the site of normal neurogenesis in adult mammals. We describe the results of a medicinal chemistry campaign to optimize the potency, toxicity profile, and stability of P7C3. Systematic variation of nearly every position of the lead compound revealed elements conducive toward increases in activity and regions subject to modification. We have discovered compounds that are orally available, nontoxic, stable in mice, rats, and cell culture, and capable of penetrating the blood-brain barrier. The most potent compounds are active at nanomolar concentrations. Finally, we have identified derivatives that may facilitate mode-of-action studies through affinity chromatography or photo-cross-linking.",
author = "MacMillan, {Karen S.} and Jacinth Naidoo and Jue Liang and Lisa Melito and Williams, {Noelle S.} and Lorraine Morlock and Huntington, {Paula J.} and Estill, {Sandi Jo} and Jamie Longgood and Becker, {Ginger L.} and McKnight, {Steven L.} and Pieper, {Andrew A.} and {De Brabander}, {Jef K.} and Ready, {Joseph M.}",
year = "2011",
month = "2",
day = "9",
doi = "10.1021/ja108211m",
language = "English (US)",
volume = "133",
pages = "1428--1437",
journal = "Journal of the American Chemical Society",
issn = "0002-7863",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Development of proneurogenic, neuroprotective small molecules

AU - MacMillan, Karen S.

AU - Naidoo, Jacinth

AU - Liang, Jue

AU - Melito, Lisa

AU - Williams, Noelle S.

AU - Morlock, Lorraine

AU - Huntington, Paula J.

AU - Estill, Sandi Jo

AU - Longgood, Jamie

AU - Becker, Ginger L.

AU - McKnight, Steven L.

AU - Pieper, Andrew A.

AU - De Brabander, Jef K.

AU - Ready, Joseph M.

PY - 2011/2/9

Y1 - 2011/2/9

N2 - Degeneration of the hippocampus is associated with Alzheimer's disease and occurs very early in the progression of the disease. Current options for treating the cognitive symptoms associated with Alzheimer's are inadequate, giving urgency to the search for novel therapeutic strategies. Pharmacologic agents that safely enhance hippocampal neurogenesis may provide new therapeutic approaches. We discovered the first synthetic molecule, named P7C3, which protects newborn neurons from apopotic cell death, and thus promotes neurogenesis in mice and rats in the subgranular zone of the hippocampal dentate gyrus, the site of normal neurogenesis in adult mammals. We describe the results of a medicinal chemistry campaign to optimize the potency, toxicity profile, and stability of P7C3. Systematic variation of nearly every position of the lead compound revealed elements conducive toward increases in activity and regions subject to modification. We have discovered compounds that are orally available, nontoxic, stable in mice, rats, and cell culture, and capable of penetrating the blood-brain barrier. The most potent compounds are active at nanomolar concentrations. Finally, we have identified derivatives that may facilitate mode-of-action studies through affinity chromatography or photo-cross-linking.

AB - Degeneration of the hippocampus is associated with Alzheimer's disease and occurs very early in the progression of the disease. Current options for treating the cognitive symptoms associated with Alzheimer's are inadequate, giving urgency to the search for novel therapeutic strategies. Pharmacologic agents that safely enhance hippocampal neurogenesis may provide new therapeutic approaches. We discovered the first synthetic molecule, named P7C3, which protects newborn neurons from apopotic cell death, and thus promotes neurogenesis in mice and rats in the subgranular zone of the hippocampal dentate gyrus, the site of normal neurogenesis in adult mammals. We describe the results of a medicinal chemistry campaign to optimize the potency, toxicity profile, and stability of P7C3. Systematic variation of nearly every position of the lead compound revealed elements conducive toward increases in activity and regions subject to modification. We have discovered compounds that are orally available, nontoxic, stable in mice, rats, and cell culture, and capable of penetrating the blood-brain barrier. The most potent compounds are active at nanomolar concentrations. Finally, we have identified derivatives that may facilitate mode-of-action studies through affinity chromatography or photo-cross-linking.

UR - http://www.scopus.com/inward/record.url?scp=79551705492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551705492&partnerID=8YFLogxK

U2 - 10.1021/ja108211m

DO - 10.1021/ja108211m

M3 - Article

VL - 133

SP - 1428

EP - 1437

JO - Journal of the American Chemical Society

JF - Journal of the American Chemical Society

SN - 0002-7863

IS - 5

ER -